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Abstract
Purpose This national, population-based study aims to de-
termine the association between the number of prescribed
medications and adverse drug events (ADE) by uninten-
tional poisoning and examine this risk when known indi-
cators of inappropriate drug use (IDU) are accounted for.
Methods We employed a matched case-control design
among people living in Sweden who were 50 years and
older. Cases experiencing an ADE by unintentional poi-
soning resulting in hospitalization or death (n = 5336)
were extracted from the National Health and Death
Registers from January 2006 to December 2009. Four
controls per case matched by age, sex and residential area
were randomly selected among those without an ADE
(n = 21,344). Prescribed medications dispensed during
the 4-month period prior to the ADE were identified via
the Swedish Prescribed Drug Register and coded accord-
ing to the number of different dispensed medications
(NDDM) (0 to 10 medications) and IDU indicators (one
single-drug, and three drug-combinations). Conditional
logistic regression was used.
Results Each of the IDU indicators was significantly associ-
ated with very high risks of ADE. For NDDM, we found a
lower but graded positive association from two to ten or more
medications (adjusted OR, 1.5; 95% CI, 1.2–1.8). Exclusion
of IDU from the NDDM decreased the risk of ADE, but the
effects remained significant for three or more medications
(adjusted OR excl. IDU, 1.5; 95% CI, 1.2–2.0).
Conclusion At population level, the number of different dis-
pensed medications starting from three or more remains asso-
ciated with ADE even after adjusting for known IDUs.
Clinicians and patients need to bemade aware of the increased
likelihood of serious ADE, not only in case of documented
inappropriate medications but also in the case of an increasing
number of medications.
Keywords Adversedrugevents .Older .Elderly .Poisoning .
Polypharmacy
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Introduction
Medications are essential for treatment of several health
conditions. Among older people, as comorbidities are
common, the number of prescribed medications is often
high [1] and that may introduce a risk for adverse events
[2, 3]. The risk may arise due to either specific medica-
tions (e.g., opioids [4]), acknowledged inappropriate
combinations of them [5], or their total number [5, 6].
One well documented serious type of medication-related
adverse event is that of being involved in an injury, like
a fall or a road traffic crash [6–9]. Unintentional poison-
ings or toxic effects are another type of adverse drug
event (ADE) less documented but there is a growing
body of epidemiological evidence on its relation to pre-
scribed medication use among older people [10–12].
ADE deserve greater attention due to their potentially
serious short- and long-term consequences, particularly
in light of the increased frailty and longer recovery time
among elderly [5, 12, 13].
There are in fact several physiological aging changes con-
tributing further to the risk of ADEs. The kidney’s decrease in
glomerular filtration rate can prolong the half-life of chemicals
and drugs and lead to accumulated toxicity levels or unexpect-
ed drug-drug interactions [14–16]. This decrease can start as
early as the age of 30–35 years [15]. A decline of liver func-
tion and a redistribution of body fat further complicate the
pharmacodynamics and pharmacokinetics of medications,
which in turn increase the risk of ADE [16–20]. As many
age-related, metabolic changes relevant to the study of
ADEs occur prior to retirement (before ± 65 years) [21, 22],
broadening the age span to include adults 50 to 64 years of age
is important, particular with regard to potentially inappropriate
medications like opioids, sedatives, cardiovascular drugs or
the combination of such [4].
Few studies have investigated ADE among older people in
light of the total number of prescribed medications, when
considering known inappropriate medications and combina-
tions. Studies of the role of inappropriate drug use (IDU) in the
association between multiple prescribed medications and
ADEs remain scarce. Thus, in this population-based, among
people of 50 years and older living in Sweden, we aim to
determine the association between number of prescribed med-
ications and ADEs, and examine this association when taking
into consideration inappropriate drug use (IDU).
Methods
Study design
We designed a matched case-control study nested in a national
cohort of 6,981,010 individuals.
Data sources
Individuals born before 1959 and living in Sweden from 1973
onwards were identified in the Total Population Register. Data
were obtained from the national health registers linked
through the unique personal identification number assigned
to all Swedish residents. The Swedish National Patient
Register and Swedish Cause of Death Register were used to
identify cases of ADE among older adults (50 years and
above) during 1 January 2006 to 31 December 2009.
Information on prescribed medications was extracted from
the Swedish Prescribed Drug Register which is a computer-
ized system of pharmaceutical services that records all dispen-
sations of prescribed drugs at all pharmacies in Sweden using
the five-level anatomical therapeutic and chemical classifica-
tion system (ATC) [23].
Case definition
Cases were defined as having been hospitalized or died due to
ADE, coded as unintentional poisonings or toxic effect by
medication and noxious substances. Hospital discharge diag-
noses were used (ICD-10 codes: T36-65 as main diagnosis
and X40-44,49 as external cause of morbidity) and for mor-
talities (ICD-10 codes X40-44,49) the underlying cause of
death was used. Only the first event of ADE was considered
during the study period. A total of 5336 cases were identified:
4950 as hospitalized and 386 as fatal. Date of death or admis-
sion to hospital was used as index date.
Selection of controls
For each case, four controls were randomly selected and
matched by age (month and year), sex and residential area at
the index date. Individuals who did not have any ADE during
the study period were eligible as controls. The total number of
controls was 21,344.
Exposure definitions
Exposure to prescribed medications was operationalized as
the total number of different dispensed medications
(NDDM) and dispensed prescriptions of IDU during the 4-
month period prior to index date. Dispensations on the index
date were not considered. Total NDDMwas determined based
on the 5th digit level of the ATC and categorized into 0, 1, 2, 3,
4, 5–9, 10 or more medications, with one medication serving
as reference group.
We adapted seven drug-specific indicators of IDU devel-
oped by the Swedish National Board of Health and Welfare
[24]. The indicators were categorized into one single-drug
category and three drug-combination categories (Table 1), in-
cluding the 15 most common drug-drug interactions in the
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Swedish population [25]. The indicators are universally appli-
cable to the elderly Swedish population and comparable to
other national guidelines on inappropriate drug use, such as
the BEERS criteria and PRISCUS list [26]. The IDU indica-
tors are not mutually exclusive and an individual can thus be
exposed to several of the indicators.
Confounders
Two potential confounder were considered: marital status,
since previous studies have shown a protective effect of being
married on other injurious ADE [27, 28] and comorbidity.
Marital status was defined based on the most recent registered
status in the Total Population Register at the index date and
categorized in married, unmarried, divorced, widowed or un-
known, and married served as the reference group. The
Charlson comorbidity index (CCI) captured individual comor-
bidity. It distinguishes 17 comorbidities according to ICD-10
codes, each weighted from one to six [29] (a higher score
represents a more severe outcome) was combined into four
categories; 0, 1–2, 3–4 and 5 or more, with 0 serving as the
reference group. CCI was based on hospital discharge diagno-
ses during the 3 years prior to the index date.
Statistical analyses
Descriptive statistics of sex, age, marital status and comorbid-
ity index were calculated and their distribution compared be-
tween cases and controls using Pearson chi-square tests.
The association between NDDM, IDUs and ADE was es-
timated by odds ratios (ORs) with corresponding 95% confi-
dence intervals (95% CIs) using conditional logistic regres-
sion. Further, the analyses were adjusted for confounders and
also stratified by age and sex. Potential confounders were
individually assessed on their association to ADE. Variables
with statistically significant effects (p value <0.05) were in-
cluded in the adjusted analysis. Marital status entailed some
missing data (n = 66, 0.002%), which were excluded from the
analysis. To explore the effect of NDDMonADE independent
of IDU analysis were performed excluding individuals ex-
posed to the IDU indicators. IBM SPSS Statistics 22 was used
to perform the statistical analyses.
Ethics
The study was approved by the Regional Ethical Review
Board in Stockholm (2010/865-31/2 and 2011/15-32).
Results
Sample characteristics
The majority of the cases were female (56.2%), older than
64 years (72.5%) and with none or less severe comorbidity
(97.6%) (Table 2). In comparison to controls, cases were less
likely to be married (34.3 vs. 46.6%) and had higher comor-
bidity levels (CCI >0: 39.6 vs.15.5%). The most commonly
prescribed medications related to fatal ADE were Zopiclone,
Oxazepam, Propiomazine, Codein and Diazepam.
IDU and ADE
Among cases, 50% had been exposed to IDU. All IDU indi-
cators showed high odds ratios, with the highest effect found
among those exposed to inappropriate single drugs (see
Supplementary S1).
Number of medications and ADE
In Table 3, the ORs of ADE when exposed to NDDM are
presented. Proportionally more cases than controls had at
least one medication during the 4 months prior to the
index date (94.9 vs. 73.9%). The odds ratios increase with
an increased number of medications in a dose-response
manner and the effect remains after taking marital status
Table 1 IDU indicators based on the definitions used by the Swedish Board for Welfare and Health [24] and Holm et al. [25]
IDU Indicator Definition
Single drug Received and dispensed a prescription for at least one long acting Benzodiazepine,
or Tramadol, or Propiomazin, or at least one anticholinergic medication
Duplicate therapy Received and dispensed prescriptions for two or more medications within
the same ATC group
Multiple psychoactive medications Received and dispensed prescriptions for at least three or more psychotropic
medications
Drug-drug interactiona Received and dispensed prescriptions for medications with known drug-
drug interaction
a Differs from the definition used by the Swedish Board for Welfare and Health and takes into account the 15most common drug-drug interactions in the
Swedish population according to the study by Holm et al. [25]
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and comorbidity into account. The highest odds ratio was
seen for 10 or more medications (adjusted OR, 14.7; 95%
CI, 12.1–17.8). When excluding those exposed to IDU,
the risk for ADEs still remains increased for those taking
three or more medications (adjusted OR, 1.5; 95% CI,
1.2–2.0).
Stratification by age and sex
Stratification by age (younger than 65 years of age and
65 years of age or older) and sex did not reveal any significant
differences between these groups (see Supplementary S2).
Discussion
This large, population-based study confirms the existing clin-
ical knowledge on the risk of specific medications for ADE,
showing that many ADEs occur among people with pre-
scribed medications known to be inappropriate. Yet, this study
also found that about half of the ADEs did not have any IDU
and among these there was a clear association with the total
number of medications. The inclusion of a wider age range,
individuals 50–64 rather than just 65 years and older, in this
study also showed that the association between the total num-
ber of medications and ADEs is already apparent among the
younger older people (>50 years).
Table 3 Percentages and odds ratios (OR) with 95% confidence intervals (95%CI) for ADE by number of different dispensed medications, n = 26,680
Number of different
dispensed medications





Matcheda Model 1b Model 1 excluding
those with IDUc
0 5.1 26.1 0.7 (0.5–0.8) 0.6 (0.5–0.8) 0.6 (0.5–0.8)
1 2.8 9.4 Ref. Ref. Ref.
2 3.5 8.7 1.5 (1.2–1.8) 1.4 (1.1–1.8) 1.3 (0.9–1.6)
3 4.1 8.6 1.9 (1.5–2.4) 1.9 (1.5–2.4) 1.5 (1.2–2.0)
4 5.5 7.9 3.1 (2.5–3.8) 2.9 (2.4–3.7) 2.1 (1.7–2.7)
5–9 32.2 26.7 6.0 (5.0–7.2) 5.4 (4.5–6.5) 2.8 (2.3–3.5)
≥10 46.9 12.7 20.1 (16.6–24.3) 14.7 (12.1–17.8) 3.8 (3.0–5.7)
aMatched by sex, age and residential area
b Adjusted for matching variables, marital status, and Charlson comorbidity index
c Excluding those with any IDU
Table 2 Characteristics of the
study population, stratified by
case and control status,
percentage (%), n = 26,680





Sex Male 43.8 43.8 Matched
Female 56.2 56.2
Age groups 50–64 years 27.5 27.5 Matched
≥65 years 72.5 72.5









*p value of Pearson chi-square tests for comparison of distribution between cases and controls
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Our study found that the risk of ADE is clearly increased
by IDU prescriptions and by increasing NDDM from two
medications onwards in a graded manner, even after exclusion
of IDU. Our findings on the associations between IDU and
multiple medications with ADE among older patients echo
previous studies [3, 5, 30], but also show that the relationship
between the number of medications and ADE appear already
at a lower number of medications prescribed than the gen-
erally accepted polypharmacy threshold of five or more
medications [3, 31].
The mechanisms for the association between NDDM and
ADEs may be complex and multifaceted. In our study, about
50% of the cases of ADE did not take any medications con-
sidered to be inappropriate. Thus, unknown drug-drug inter-
actions might be one way of explaining this, particularly since
research on drug interactions between three or more medica-
tions is scarce. Undetectable interactions of prescribed medi-
cations and over-the-counter medications, herbal treatment
and food substances might also add to the increased risk.
Even though most of the ICD-10 codes for ADE by uninten-
tional poisoning are defined by exposure to a specific medi-
cation, e.g., poisoning by systemic antibiotics, we found that
5.1% of the ADE cases did not have any dispensations of
prescribed medication in the previous 4 months. The ADEs
among these could be due to medications that were prescribed
earlier, for example, with an Bon-need basis.^ However, this
could also be due to over-the-counter medications, which our
register does not account for. Decreased cognitive functions,
typical among the elderly, can also lead to faulty medication
use including wrong dosages or intake of someone else’s
medications [32].
Strengths and limitations
Similar approaches to identification of ADEs by unintentional
poisoning, based on specific and appropriate ICD diagnoses
from the hospitalization and death register, have been
employed earlier [33–35]. These studies were also challenged
by the use of discharge diagnoses classified according to
ICD-10. Other studies have focused on specific clinical pa-
tient groups and the underlying mechanism of their diseases
and prescribed medications, i.e., chronic kidney diseases [2].
Yet, it is more challenging to disentangle the role of diseases,
comorbidities and medications in large population settings
when the indication for prescription, which is not available
in the registers, cannot be analyzed. In order to address the
influence of diseases and comorbidities, we employed the
Charlson comorbidity index which is mostly applicable in
hospital settings when considering older adults’ chronic or
severe diseases [36]. The index takes into account serious
diseases that require treatment in hospital. Adjustment for this
and marital status only slightly decreased the associations, but
more so among those with many medications indicating that
serious morbidity has been adjusted for. However, one limita-
tion is that we were not able to adjust for morbidity not requir-
ing hospitalization.
The main strengths of this study lie in the linkage of an
individual’s information through the use of various Swedish
registers, both for assessment of ADE, dispensations of med-
ications and the potential confounders. The registers cover the
entire Swedish population and are continuously updated, and
as a result the study yields results that can be generalized to the
entire older adult population in Sweden. By using register
information, we prevent recall bias that is often a serious bias
in case-control studies with retrospective information.
Although the use of register information on medications has
many advantages, it does not inform about actual intake or
over-the-counter medications, which might lead to some de-
gree of misclassification [37], although non-differential
among cases and controls. Our study focuses on dispensations
of prescribed medications, which is a better proxy for actual
intake than mere prescriptions. Furthermore, none of the ac-
tive ingredients related to the IDU indicators can be purchased
without a prescription in Sweden. In general, the Swedish
regulations are quite restrictive for the availability of medica-
tions. In settings where the access to over-the-counter medi-
cations as well as prescribed medications might be less regu-
lated, the magnitude of the problem might be even greater.
We focused the exposure period to the 4 months prior to the
index date in order to assess medications close to and current
at the time of the ADE. In Sweden, medications are normally
prescribed for a treatment period of 3 months, thus the chosen
4-month period would capture potential changes regarding
chronic medication use that have long prescription routines.
However, changes or substitutions of medications of the same
kind would not be overestimated as different medications giv-
en that they lie within the same ATC code. Other
pharmacoepidemiological studies using dispensation systems
have shown that too narrow time intervals can result in up-
wards bias [38]. On the other hand, the time interval might
miss medications prescribed on an according-to-need basis,
leading to an underestimation of the total number of medica-
tions, though any over- or under-estimation in this setting
would apply in the same manner to cases and controls.
We cannot rule out some degree of inaccuracy in reporting
based on the registers as physicians might misdiagnose ADEs
due to an unspecific presentation, especially among older in-
dividuals [3, 17]. Similar studies using other injurious events
can rely on ICD-10 codes with more common injury manifes-
tations as outcome, e.g., injuries due to falls as they are sim-
pler to define and easier to categorize when clinically present-
ed. Although attempts have been made to define ADE using
ICD-10 code algorithms with acceptable sensitivity and sen-
sibility [35], the ICD-10 codes for ADEs are scattered and
unspecific, e.g., ICD-10 T50 defines ADE by diuretics and
unspecified drugs, and even a more specific T50.9 still
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combines ADE by medications and other substances.
Furthermore, ADEs can be missed, since the diagnoses in
ICD-10 potentially could involve unintentional poisoning by
medication without defined by sub-codes that state the in-
volvement of a medication, e.g. E87.1 hyponatremia, a coding
not used in this research, does not have any further specifica-
tion on the possible involvement of a medication, but could be
considered an ADE.
Conclusion
At population level, both NDDM and IDU are associated with
an increased risk of ADE by unintentional poisoning among
older. The number of different dispensed medications starting
from three or more remains associated with ADE even after
adjusting for known IDUs. At population level, clinicians and
patients need to be made aware of the increased likelihood of
serious ADE, not only in case of documented inappropriate
medications but also in the case of an increasing number of
medications.
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